Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IL18 | Q14116 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429144 | 1.00 | PARP15 (0.44) | PARP15PARP10PARP2KDM4EMEN1 | |
| SCHEMBL28874965 | 0.84 | PARP15 (0.41) | PARP15PARP10PARP2KDM4EMEN1 | |
| SCHEMBL22053624 | 0.84 | PARP15 (0.46) | PARP15PARP10PARP2KDM4EMEN1 | |
| SCHEMBL16555444 | 0.83 | EPAS1 (0.50) | — | |
| SCHEMBL2531379 | 0.82 | AR (0.45) | CYP19A1KCNH2MERTK | |
| SCHEMBL2528151 | 0.82 | EPAS1 (0.40) | CA1CA2CA9CA12KCNH2 | |
| SCHEMBL2529786 | 0.82 | PDE4B (0.46) | KDM4ELMNAPOLBMAPTMAPK1 | |
| SCHEMBL1351408 | 0.81 | RAD51 (0.42) | MEN1LMNAKMT2ACA1CA2 | |
| SCHEMBL11490625 | 0.80 | LMNA (0.50) | MEN1LMNAKMT2ACA1CA2 | |
| SCHEMBL21064823 | 0.80 | SOS1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018115362-A1 | PROCESS FOR PREPARING 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL)OXY]BENZONITRILE (CRISABOROLE) | LABORATORIOS LESVI, SL (ES) | 2018-06-28 | — | — | WO | claimed |
| WO-2024094235-A1 | USE OF BENZOXABOROLE-BASED COMPOUNDS IN THERAPY OF DISEASES CAUSED BY AMOEBAS OF THE NAEGLERIA GENUS | UNIVERZITA KARLOVA (CZ) | 2024-05-10 | — | — | WO | disclosed |
| CN-113801089-B | Preparation method of clenbuterol intermediate | 鲁南制药集团股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-113387971-B | Synthesis method of clenbuterol | 安徽普利药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116925117-A | Preparation method of clenbuterol and intermediate thereof | 浙江九洲药业股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11708382-B2 | Process for the preparation of highly pure Crisaborole | HALCYON LABS PRIVATE LIMITED (IN) | 2023-07-25 | — | — | US | disclosed |
| US-11708382-B2 | Process for the preparation of highly pure Crisaborole | HALCYON LABS PRIVATE LIMITED (IN) | 2023-07-25 | — | — | US | disclosed |
| CN-116239498-B | Method for preparing clenbuterol intermediate | 北京元延医药科技股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116253756-B | Preparation method of clenbuterol | 北京元延医药科技股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116253756-A | Preparation method of clenbuterol | 北京元延医药科技股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-10981939-B2 | Process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (Crisaborole) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2021-04-20 | — | — | US | disclosed |
| US-20210070778-A1 | NOVEL PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2021-03-11 | — | — | US | disclosed |
| CN-109456347-B | Preparation method of clitorium | 安徽省庆云医药股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3737685-A1 | PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | Halcyon Labs Private Limited (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200172560-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2020-06-04 | — | — | US | disclosed |
| US-20200062785-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL) OXY] BENZONITRILE (CRISABOROLE) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD., (IN) | 2020-02-27 | — | — | US | disclosed |
| WO-2018224923-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018115362-A1 | PROCESS FOR PREPARING 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL)OXY]BENZONITRILE (CRISABOROLE) | LABORATORIOS LESVI, SL (ES) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115362-A1 | PROCESS FOR PREPARING 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL)OXY]BENZONITRILE (CRISABOROLE) | LABORATORIOS LESVI, SL (ES) | 2018-06-28 | — | — | WO | disclosed |
| EP-2564857-B1 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062785-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL) OXY] BENZONITRILE (CRISABOROLE) | CYP4B1, CYP8B1, CYP4X1 | PARP15 2149/4885PARP10 3031/4885PARP2 2340/4885 |
| US-20210070778-A1 | NOVEL PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | UGT2B17, SQLE, CYP11B1 | PARP15 1308/4885PARP10 2114/4885PARP2 4072/4885 |
| US-20200172560-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | CFB, F13B, C9 | PARP15 1819/4885PARP10 3652/4885PARP2 2961/4885 |
| US-11708382-B2 | Process for the preparation of highly pure Crisaborole | SQLE, UGT2B17, CYP2C19 | PARP15 1370/4885PARP10 2750/4885PARP2 4160/4885 |
| US-10981939-B2 | Process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (Crisaborole) | CYP4B1, CYP8B1, SQLE | PARP15 1896/4885PARP10 3047/4885PARP2 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.